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SUMMARY 
Background: Despite the dissemination of second generation antipsychotics for schizophrenia and bipolar disorder, outcomes 
remain suboptimal, largely due to poor treatment and drug adherence. The primary aim of the current study was to assess the 
tolerability, validity and feasibility of the pocket-sized electronic diary Medicus®. 
Subjects and methods: Our case observations attempted to evaluate eighteen patients suffering from schizophrenia and bipolar 
disorder. All of the patients were treated with the second generation antipsychotic quetiapine. We followed them up in two German 
medical centers over two years.  
Results: The present results display an improvement of mood-stability in all patients treated with quetiapine. All patients were in 
regular contact to their psychiatrist over a period of 24 months. A complete description of the coherences between the symptoms was 
essential for estimation, which was conducted by Medicus®. Moreover, Medicus® seem to be useful for improving compliance within 
a medication regimen. 
Conclusions: Although uncontrolled case observations can only be interpreted with caution, Medicus® seems to deserve further 
investigation and may hold the potential to optimize treatment and drug adherence in patients suffering from schizophrenia and 
bipolar disorders. 
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INTRODUCTION 
Outcomes in antipsychotic treatment of bipolar 
disorders and schizophrenia with drugs remains sub-
optimal, mainly due to poor treatment and drug adhe-
rence (Goff et al. 2011, Kane 2011, Loga-Zec & Loga 
2010). Reduced compliance with antipsychotic medica-
tion increases relapse and rehospitalization rates in 
patients with schizophrenia and bipolar disorders (Laan 
et al. 2010). The most frequently reasons patient-related 
factors contributing to the partial compliance are lack of 
insight into the need for prophylactic medication, lack 
of insight/denial of illness, feeling embarrassed at taking 
medication every day, needing someone to remind them 
to take their medication, cognitive problems, and living 
conditions inappropriate for compliance (Beck et al. 
2011). Main strategies to improve compliance derived 
from these patient-related factors could be psycho-
education and regular drug reminders (Goff et al. 2010, 
Pitschel-Walz et al. 2011). However, therapist-related 
factors are also important to improve drug compliance 
(Dolder et al. 2003, Mutschler et al. 2011, Mutschler et al 
2012). Therefore precise estimates of the current symp-
toms of psychotic disorders are necessary to evaluate and 
adapt antipsychotic treatment comprehensively (Agya-
pong et al. 2009). Relying on recall of symptoms form 
patients does not allow a longitudinal assessment in 
naturalistic environments, and fail to incorporate the 
multidimensional nature of psychotic symptoms. 
Electronic diary methods, using real-time data capture, 
are a tool to serve with those difficulties (Burton et al. 
2007, Piasecki et al. 2007). Electronic diaries minimize 
recall bias by enabling collection of real-time data from 
patients. Moreover, electronic diaries can remind patients 
to take their medications by a ring tone (Burton et al. 
2007, Piasecki et al. 2007). 
However, research on the use of electronic diaries in 
patients suffering from schizophrenia and bipolar 
disorders is limited. In this case series the validity and 
feasibility of the pocket-sized electronic diary Medicus® 
was examined in patients suffering from schizophrenia 
and bipolar disorders and being treated with the second 
generation antipsychotic quetiapine. The Medicus®-
system was sought to determine the ability of the diary 
to detect mood-instability and improve individual drug 
compliance. 
 
SUBJECTS AND METHODS  
Subjects 
All eighteen patients (10 males, 8 females; aged 
between 18 and 65 years) fulfilled the diagnostic criteria 
for schizophrenia and bipolar disorder according to 
ICD-10 and DSM IV, and did not suffer from any other 
psychiatric disorder (clinical interview by a psychiatrist) 
Jochen Mutschler, Falk von Zitzewitz, Wulf Rössler & Martin Grosshans: APPLICATION OF ELECTRONIC DIARIES IN PATIENTS  
WITH SCHIZOPHRENIA AND BIPOLAR DISORDERS          Psychiatria Danubina, 2012; Vol. 24, No. 2, pp 206–210 
 
 
 207
or addictive disorder (except tobacco dependence). We 
present data of a retrospective case study of persons 
with schizophrenia or bipolar disorder. Patients with one 
of the mentioned diagnosis were consecutively asked, if 
they were willing to use the electronic diary. There were 
no exclusion criteria. According to the local ethics 
committee it is permitted to retrospectively analyze 
anonymous clinical data for research purposes. All 
patients gave written informed consent.  
 
Medication 
All patients were treated weekly to monthly by a 
psychiatrist in an outpatient setting. Initially, we only 
intended to observe the patients for 12 months, 
however, all of them visited our outpatient department 
regularly up to 24 months. Therefore, we decided to 
report the full-length observation time. We started 
quetiapine with 100 mg/day in the evening, dosage 
adjustment was done according to the clinical effect. 
Since sedation in quetiapine increases with reduction of 
dosage (clinical experience), we reduced the dosage in 
increments of 25 mg/day till sleep was reported to be 
good. In contrast, we increased dosage up to 200 mg/day 
in increments of 25 mg/day if the patient reported 
sleepiness in the daytime. The dosage was adjusted 
according to clinical response targeting at about 200 mg 
per evening and ranged from 100 to 200 mg/day. 
 
Electronic diary 
Current mood and three sub-classes of mood 
disorder (tiredness, agitation and anxiety) were assessed 
by Medicus®. Before they were recruited, physician 
assistants instructed the participants in using the 
electronic diary-system. 
The system was individually programmed with the 
drug dosages and therapy times of every participant. The 
patients were reminded by a ring tone when it was time to 
take the next dosage of quetiapine. Additionally, the 
participants documented their medication intake as well 
as their mood-qualities by pressing the keys on the 
system. Medicus® is endued with four buttons: M 
documents medication intake, W symptoms and two 
buttons document diverse steps of condition. Up to 11 
degrees are possible. In this study eight steps (--, -, (-), 0, 
(+), +, ++ and +++) were set to acquire the degree of 
patient condition. Time and date were automatically re-
gistered. The patients´ condition and its intensity could be 
captured at any time. The measured data were visualized 
by graphics on a computer screen. Compliance and re-
sults of treatment were viewable at any point of the treat-
ment. Further details on Medicus® are described at 
http://medicus.eu/. All participants gave informed consent. 
 
Statistical analysis 
Descriptive statistics are given when appropriate 
(mean ± SD). 
RESULTS 
After a two-year-period of monitoring, the results of 
this investigation showed that the choice of motivated 
physician assistants offered the possibility for indivi-
duals with schizophrenia or bipolar disorders to use 
Medicus® without problems. The recording-procedures 
worked well and the participants report that the device 
is easy to handle. The recorded data gave important 
insights in the process of disease and could be 
immediately statistically analyzed by the computer 
system. A continuous observation of the individual 
symptoms and drug side effects was possible. The 
results offer an improvement in mood by treatment with 
quetiapine. Additionally, some participants of this study 
suffered from schizophrenia with severe mood swings. 
By using Medicus® data quetiapine dosage was adjusted 
which was followed by a reduction of mood swings and 
a stabilized affect. For details see Figure 1 (this example 
was elected, because it demonstrates a typical course) 
and Table 1. 
In the patients observed, and treated with quetiapine, 
we found a good clinical overall-response and no 
serious adverse events have been recorded during the 
course of the study. As expected, the most prominent 
adverse event of quetiapine was tiredness and sedation 
in particular during daytime. It should be noted that in 
each case, a few weeks after the start of quetiapine and 
adjustments of the daily dosage administered, tiredness 
and/or sedation disappeared. Furthermore, our data 
display good tolerance and safety. 
 
DISCUSSION 
The present study evaluated the feasibility of using a 
specially designed computerized device, Medicus®, for 
the treatment of patients with schizophrenia and bipolar 
disorders. Our data suggest that many patients are 
willing and able to use this kind of treatment-supporting 
technology.  
Although many of the participants had never used 
computers, and many had cognitive limitations, all 
subjects were successfully trained to use Medicus®, and 
were able to use the device on their own at home. This 
suggests that socioeconomic status, cognitive difficult-
ties, and other variables associated with schizophrenia 
and bipolar disorders are not limiting factors in using 
computer devices specifically designed for monitoring 
patients.  
Medicus® was useful to improve compliance with 
medication regimens. All participants could be followed 
up two years. The patients in this study reported taking 
their medication more regularly, which is likely to be a 
result of the monitor’s prompting. However, if patients 
finally took their medications more regularly has not 
been verified and has to be proven in a future study 
(e.g., by measuring plasma levels of the medication). 
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Table 1. Cross-sectional illustration of the subjective scores, indicated the manifestation of the degree of the different 
emotional states (-- = severe symptoms; - = mild symptoms; 0 = no symptoms/balanced emotional state, + = good; ++ = 
very good) 
Patient Mood Tiredness Agitation Anxiety 
1 + ++ + ++ 
2 + - + ++ 
3 + - ++ ++ 
4 + + + + 
5 -- + -- -- 
6 + - + + 
7 ++ - ++ - 
8 + ++ -- 0 
9 0 + + 0 
10 + -- - 0 
11 - -- - - 
12 0 0 0 0 
13 (-) (-) -- - 
14 -- - + + 
15 ++ ++ - - 
16 + ++ - - 
17 - -- -- - 
18 ++ (-) (+) 0 
 
time (days)
 
The y-axis represents a subjective impression of the different emotional states: -2= severe symptoms; -1= mild symptoms; 0 = no 
symptoms/balanced emotional state, 1= good emotional state; 2= very good emotional state. On the x scale the recorded time period in 
days is plotted. A complete description of all parameters was essential for evaluating the coherence of the parameters. Medicus® 
visualized the process in disease and included all parameters. Figure 1 shows an example.  
Figure 1. Graphic demonstration of all parameters in patient 8 (paranoid schizophrenia). For evaluation the coherence 
between mood and tiredness we used polygnomic demonstration  
 
The monitor maybe an effective tool for preventing 
or reducing relapse in chronic diseased patients, 
however, this also has to be proven in future studies. It 
is well known that drug non-compliance is one 
important factor contributing to the maintenance of 
schizophrenia or bipolar disorder (Goff et al. 2011, Laan 
et al. 2010). 
During the trial, if individual symptoms increased, 
data were reported immediately to the clinical staff. 
Therefore, clinical interventions were timely, and 
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targeted the specific symptoms reported by patients. 
This process allowed clinicians to be efficient and 
effective and may have prevented relapses among the 
participating patients. 
The combination of elements offered in this study -
receiving patient information about symptoms, 
monitoring the symptoms, and responding quickly to 
changes - may be particularly helpful for patients with 
schizophrenia, bipolar disorders or other illnesses in 
which timely intervention is a key factor in preventing 
or reducing relapses. The ability to provide rapid, 
targeted interventions may also be helpful in clinical 
drug trials, to promote patient adherence to their 
protocol, and complete the trial more promptly. 
An important aspect of this study was the daily 
transmission of educational facts about the disease and 
medications. Consequently, the majority of participants 
reported having learned more about schizophrenia, 
bipolar disorders, and medication. Furthermore, 
participants gained increased awareness of the 
association between individual symptoms and 
medication adherence, potentially increasing future 
adherence to medication regimens. 
Almost all of the participants in this observation 
report positive experiences with the Medicus®-system. 
It is likely that patients who believe in the efficacy of 
the Medicus®-system will continue to use it device even 
during difficult episodes (e.g., symptom exacerbations, 
personal problems, technical difficulties with the 
equipment, or simply boredom with the routine). 
Furthermore, patients who are content with this medical 
system are more likely to convey these feelings to other 
individuals suffering from similar diseases. Word-of-
mouth plays an important role in engaging potentially 
resistant patients in a new process, especially in inner 
city clinics. 
The current findings support the use of Medicus® 
not only for clinical practice, but also for future clinical 
drug trials. Current methods in clinical trials to monitor 
participants and collecting data often rely upon paper 
and pencil diaries and/or pill counts to assess parameters 
like symptom response, side effects, adverse events, and 
medication compliance. These methods lack the 
accuracy of a real time data capture, and the daily dose-
response monitoring capabilities of a system like 
Medicus®. Traditionally, participants in clinical trials on 
schizophrenia or bipolar disorders are being instructed 
with written protocols how to take part in the study. But 
many of those study participants suffer from cognitive 
problems which may be a bias in later data analyses, 
therefore a simple and reliable data recording system 
might improve the efficacy of this kind of studies. 
The next, more sophisticated generation of this 
system, Medicus II® will contain better documentation 
capabilities in order to evaluate polypharmacological 
treatment and dose-response-relationships. However, 
some limitations the investigation presented here should 
be mentioned. The number of cases is low and we did 
not recorded data from a control group Furthermore, 
psychopathology was not assessed with standardized 
questionnaires. One might speculate that the electronic 
device per se might have an impact on the clinical 
outcome and compliance. Thus, we strongly recommend 
controlled clinical trials to further evaluate our 
preliminary findings. 
 
CONCLUSION 
The results of this preliminary study suggest that the 
use of a specialized electronicdevice is feasible in 
clinical monitoring, and in the treatment of 
schizophrenia and bipolar diseases. All participating 
patients and clinicians described the system as useful, 
easy to handle, satisfying, and educational. In addition, 
future studies should expand the current data by 
including other populations from a variety of 
perspectives such as medication adherence, symptom 
management and education.  
 
Acknowledgements: None. 
Conflict of interest : None to declare. 
 
REFERENCES 
1. Agyapong VI, Nwankwo V, Bangaru R, Kirrane R: 
Sources of patients' knowledge of the adverse effects of 
psychotropic medication and the perceived influence of 
adverse effects on compliance among service users 
attending community mental health services. J Clin 
Psychopharmacol 2009; 29:565-70. 
2. Beck EM, Cavelti M, Kvrgic S, Kleim B, Vauth R: Are we 
addressing the 'right stuff' to enhance adherence in 
schizophrenia? Understanding the role of insight and 
attitudes towards medication. Schizophr Res 2011; 
132:42-9. 
3. Burton C, Weller D, Sharpe M: Are electronic diaries 
useful for symptoms research? A systematic review. J 
Psychosom Res 2007; 62:553-61. 
4. Dolder CR, Lacro JP, Leckband S, Jeste DV: 
Interventions to improve antipsychotic medication 
adherence: review of recent literature. J Clin 
Psychopharmacol 2003; 23:389-99. 
5. Goff DC, Hill M, Freudenreich O: Strategies for 
improving treatment adherence in schizophrenia and 
schizoaffective disorder. J Clin Psychiatry 2010; 71 (suppl 
2):20-6. 
6. Goff DC, Hill M, Freudenreich O: Treatment adherence in 
schizophrenia and schizoaffective disorder. J Clin 
Psychiatry 2011; 72, e13. 
7. Kane JM: Improving treatment adherence in patients with 
schizophrenia. J Clin Psychiatry 2011; 72, e28. 
8. Laan W, Does Y, Sezgi B, Smeets HM, Stolker JJ, Wit NJ, 
Heerdink ER: Low treatment adherence with anti-
psychotics is associated with relapse in psychotic 
Jochen Mutschler, Falk von Zitzewitz, Wulf Rössler & Martin Grosshans: APPLICATION OF ELECTRONIC DIARIES IN PATIENTS  
WITH SCHIZOPHRENIA AND BIPOLAR DISORDERS          Psychiatria Danubina, 2012; Vol. 24, No. 2, pp 206–210 
 
 
 210
disorders within six months after discharge. Pharmaco-
psychiatry 2010; 43:221-4. 
9. Loga-Zec S & Loga S: Antipsychotics and the quality of 
life of schizophrenic patients. Psychiatr Danub 2010; 
22:495-497. 
10. Mutschler J, Dirican G, Gutzeit A, Grosshans M: Safety 
and efficacy of long-term disulfiram aftercare. Clin 
Neuropharmacol 2011; 34:195-8. 
11. Mutschler J, Eifler S, Dirican G, Grosshans M, Kiefer F, 
Rössler W, Diehl A: Functional social support within a 
medical supervised outpatient treatment program. Am J 
Drug Alcohol Abuse 2012 (Epub ahead of print). 
12. Piasecki TM, Hufford MR, Solhan M, Trull TJ: Assessing 
clients in their natural environments with electronic 
diaries: rationale, benefits, limitations, and barriers. 
Psychol Assess 2007; 19:25-43. 
13. Pitschel-Walz G, Gsottschneider A, Frobose T, Kraemer 
S, Bauml J, Jahn T: Neuropsychology of psychoeducation 
in schizophrenia : Results of the Munich COGPIP study. 
Nervenarzt 2011 [Epub ahead of print]. 
Correspondence: 
Jochen Mutschler, MD 
Department of General and Social Psychiatry, Psychiatric University Hospital Zürich 
Militärstrasse 8, P.O. Box 1930, 8021 Zürich, Switzerland 
E-mail: jochen.mutschler@puk.zh.ch 
